share_log

藥明合聯:自願性公告 不尋常價格及交投量變動

WUXI XDC: VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

Hong Kong Stock Exchange ·  Mar 6 23:29
Summary by Moomoo AI
藥明合聯生物技術有限公司(「藥明合聯」)於2024年3月7日發布自願性公告,指出公司股份在香港聯合交易所有限公司的價格及交投量近期出現不尋常變動。藥明合聯經合理查詢後確認,目前不知悉任何應披露的內幕消息,並強調公司業務及財務狀況維持正常,無重大變動。公司提醒股東及潛在投資者交易時應保持謹慎。公告由執行董事兼首席執行官李錦才博士代表董事會發出。
藥明合聯生物技術有限公司(「藥明合聯」)於2024年3月7日發布自願性公告,指出公司股份在香港聯合交易所有限公司的價格及交投量近期出現不尋常變動。藥明合聯經合理查詢後確認,目前不知悉任何應披露的內幕消息,並強調公司業務及財務狀況維持正常,無重大變動。公司提醒股東及潛在投資者交易時應保持謹慎。公告由執行董事兼首席執行官李錦才博士代表董事會發出。
Pharmaceutical Union Biotechnology Co., Ltd. (“Pharmaceutical Union”) issued a voluntary notice on 7 March 2024, noting that recent unusual changes in the price and trading of the Company's shares on the Hong Kong Stock Exchange Limited have been unusual. After reasonable enquiries, the Pharmaceutical Union confirms that it is not aware of any inside information to be disclosed at this time and emphasises that the company's business and financial condition remains normal without significant changes. The Company reminds shareholders and potential investors to exercise caution when trading. The announcement was made by the Executive Director and Chief Executive Officer, Dr. Lee Kam Chai, on behalf of the Board.
Pharmaceutical Union Biotechnology Co., Ltd. (“Pharmaceutical Union”) issued a voluntary notice on 7 March 2024, noting that recent unusual changes in the price and trading of the Company's shares on the Hong Kong Stock Exchange Limited have been unusual. After reasonable enquiries, the Pharmaceutical Union confirms that it is not aware of any inside information to be disclosed at this time and emphasises that the company's business and financial condition remains normal without significant changes. The Company reminds shareholders and potential investors to exercise caution when trading. The announcement was made by the Executive Director and Chief Executive Officer, Dr. Lee Kam Chai, on behalf of the Board.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more